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INTRODUCTION
'{t is not difficult, in 1985, to give a scheme of the biochemical
reactions that cause blood to clot. There is general consensus on
the mechanism that causes plasma coagulation, either when trig-
gered by contact with glass or orther foreign surfaces or when
recalcified in the presence of an excess of tissue thromboplastin,
that is, via the intrinsic or extrinsic pathway.
Much is known about the individual reactions that constitute
these pathways, especially since in the last few years obtaining the
individual clotting factors in a pure and functional state is no pro-
blem any longer in the specialized laboratory, so that kinetic stu-
dies on isolated steps of the coagulation mechanism can reveal the
details of the biochemical mechanism involved.
It may seem that the bulk of investigations in the field has
been done and that sufficient knowledge has been gathered to
explain how thrombin is formed during haemostasis and thrombo-
sis.
It is slightly uncomfortable then to realise that we do not know
much about the mechanism of thrombin formation in vivo, or even
exyivo, i.e. in whole plasma, unless we know what reactions that are
biochemically possible govern the kinetics of the process.
The standard schemes of blood coagulation do not answer
some simple, every day questions that every hematologist is able to
formulate, such as : Why do hemophiliacs bleed whereas the pro-
band of Factor XII deficiency, Mr. Hageman, had no bleeding pro-
blems and died of thrombosis ? Why do a large proportion of Fac-
tor XI defrcient patients show no signs of a haemorrhagic tendency
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whereas others do ? Why is it that heparin hardly influences the
thromboplastin time and, in the same concentrations has a marked
influence both on the thrombin time and the activated partial
thromboplastin time ? Why do some kinds of thrombopathy show
clotting disorders whereas most do not etc. etc.
Even evident questions like : < If thrombin is necessary to
activate factor V (or factor VIII) and if on the other hand factor Vu
(factor VIIIJ is necessary to form thrombin, then what sets the sys-
tem going in the first place ? >, do not find a ready answer.
In fact the main lines of the coagulation scheme as it is com-
mon knowledge at present, explain that thrombin forms in the test
tube in the presence of either an excess of thromboplastin or of
kaolin and phospholipid. It does not however answer how the
mechanism is triggered, regulated and limited in vivo, or even in
whole plasma under conditions that approach the in vivo situation,
such as the presence of limited amounts of thromboplastin, blood
platelets etc. etc.
In the course of the years many reactions between different
clotting factors have been described apart from the main pathways
of inkinsic and extrinsic coagulation. Some of them have been
found in whole plasma, others in purified preparations. In fact so
many of these cross reactions have been established that, on the
one hand, it seems easy to explain away some of the problems men-
tioned above by inserting one or more of these reactions where
necessary, in the existing reaction schemes. On the other hand,
there is hardly any indication as to which of the cross reactions are
indeed important in vivo and which are not.
In an attempt to approach this problem we will a) give an out-
line of the classical coagulation mechanism b) make an inventarisa-
tion of the most important cross reactions and c) discuss a possible
approach to some of the questions posed.
A. THE CLASSICAL COAGULATION MECHANISM
1. AeErve,rtoN By LTMITED pRorEol-ysts
The mechanism of activation by limited proteolysis is central
in the bloodcoagulation reaction sequence. In fact the principle of a
proenzyme enzyme conversion has been discovered in blood coa-
gulation when Pekelharing in 1894 isolated a thromboplastin - and
fibrinogen free fraction of plasma that could be activated by tissue
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thromboplastin and Ca++ so as to render a solution that could clot a
preparation of fibrinogen (1, 2).
The studies on digestive proteolytic enzymes ((chymo)trypsin,
pepsin etc) and their zymogens have made proenzyme + enzyme
conversions of proteolytic enzymes one of the main subjects of
classical enzymology (3, 4).
The main chain of tissue thromboplastin induced proteolytic
activations is x :
V [=X - I I
For intrinsic coagulation the main chain of activations is (5) :
PK=X I I *X I -X - i l
All the non-activated clotting factors participating in these
chains are proenzymes of serine proteases, the activated enzymes
consequently are serine proteases.
2. HersnocENEous BTocATALYsIS
The proteolytic activations shown above can be obtained when
the molecules are solved in the aqueous phase. They are accelerat-
ed up to 100.000 fold however by the presence of a phospholipid
interface and specifrc protein cofactors. To illustrate this mechan-
ism we will take the activation of prothrombin as an example. Fac-
tor X" is capable to generate thrombin for prothrombin in free solu-
tion, but only in a very ineffective mechanism (6,7,8) Hanahan &
Pappahadjopoulos (9) were the first to observe that an active pro-
thrombinase exist only in preparations that contain the three com-
ponents FXa, FV and phospholipid. (The question of factor V acti-
vation will be discussed later). Hemker et al (10) showed that the
generation of prothrombinase activity can be described as the
reversible formation of a complex of FXu, FV and phospholipid. In
a series of very elegant experiments Rosing et all (11) later showed
that phospholipid deminish the K. of the prothrombin conversion
(a typical change would be from 3000 nM to 30 nM) whereas Fac-
tor V" increases the turnover number (k.ut) about 1000 fold.
* Arrows indicate activation steps, double affows mean mutual activation.
Brackets indicate multienzyme complexes.
PK : prekallikrein, TF : Tissue Factor, PL : phospholipids.
Roman numerals indicate the factors.
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Further investigations (11-18) showed that the change in K. is
caused by the fact that the lipid bound enzyme has a higher affinity
for the substrate then the free enzyme has. The change in k"* is
probably brought about by an alignment of the active-site of Fac-
tor Xu to the vulnerable sites of Factor II caused by their mutual
interactions with Factor Vu.
lnl967 Hemker and Kahn (19) found that the Factor X activat-
ing en2yme is a complex of the Factors VIII. and IXu and phospho-
lipid, completely comparable to the prothrombinase complex. La-
ter van Dieijen et al (20) showed that in this complex the kinetic
effects of phospholipids (on K-) and Factor VIII. (on k"J were
similar to those of PL and Factor Vu in the prothrombinase com-
plex.
Apart from their kinetic effect on k"u1, the factors Vu and VIII"
also serve to better bind their resp. enzymes (FXu and FIX) to
phospholipid (21, 22).
The available data, primarily those coming from the laboratory
of Nemerson (23) indicate clearly that Factor VII and tissue throm-
boplastin form a complex that is again comparable to prothrombi-
nase. In this case the protein cofactor and the phospholipid are inti-
mately bound but the mechanistic-role of the protein factor, like
Factor Vu, seems to be enhancing'the efficiency of the enzyme
whereas the lipid serves to booster the affinity for the substrate.
The most obvious difference with the other complexes resides in
fact that tissue thromboplastin does not arise from an on the spot
combination of the protein cofactor and the lipid but is a tight com-
plex, shed as such by wounded cells. We will not enlarge upon the
surface reactions and cofactors of contact activation here for rea-
sons that will be discussed later.
We can summarize the reactions of the classical coagulation
pathways as follows :
Extinsic pathway.
(vII,  TT, PL)€(X, Vu, PL)*II
Intrinsic pathway.
PK= XII * y1* (IX, VIII., PL) *(X, Va, PL) * IJ
An overview of the coagulation reactions is not complete if no
account is given of the way in which thrombin formation is limited.
Apart from the trivial possibility of substrate exhaustion, more
often then not silently assumed to be the clotting delimiter in the
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older literature, there are two main mechanisms to be considered :
scavenging of coagulation proteases by antithrombin in III, o2
macroglobulin and other antiproteases (see 24 for a review) and
breakdown of the protein cofactors (FV" and FVIII") by activated
protein C (together with protein S) (25,26). Protein C and protein S
are vitamin K dependent proteins circulating in the plasma(27 ,28).
Protein C is activated by thrombin adsorbed onto thrombomodu-
lin (29). Because thrombomodulin occurs at the surface of intact
endothelium this mechanism may help to limit thrombin forma-
tion to wounded areas.
Among the anti-proteases AT III is extremely important
because of the fact that its activity can be enhanced by hepa-
rin (30-32) which makes it the lever on which this important family
of antithrombotic drugs acts.
B. THE CROSS REACTIONS
1. AcrrvenoNs oF clorrrNc FACToRS By THRoMBIN
It has been shown that both Factor VIII and Factor V have to
be activated before they can play their role as a protein cofactor,
and" that thrombin is the enzyme that brings about these activa-
tions (33-36). Thrombin-activated Factor V (F'VJ in a purified
state, when kept under the right conditions is relatively stable. The
activation state of factor VIII is always a transitory phenomenon,
ending in inactivation. The activation of Factor V has been des-
cribed in terms of protein chemistry. The one chain molecule of
Factor V is cleaved in three places by thrombin and two of the four
resulting fragments recombine under the influence of Ca++ to
form Factor Vu. The mode of interaction between Factor VIII and
thrombin is still essentially unknown. It has been described that in
a human system Factor X" can activate Factor VIII (37).
At this moment it may considered to be established beyond
any doubt that activation of the Factors V and VIII is obligatory for
them to take part in the coagulation mechanism. This does not
mean however that we know whether these reactions are physiolo-
gically important. To be more exact : it is essential to know whether
these activations play a rate limiting role under physiological condi-
tions and what the physiological activator is. From the work of Hur-
let et al (38) it may be concluded that the activation of V and VIII
does not occtr invivoin the time course of normal haemostasis but
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this again does not allow conclusions as to its factual importance.
Such conclusions might be drawn if an aberrant prothrombin were
known that yield a thrombin incapable of activating Factor Y, pro-
thrombin Metz(39,40) might be a candidate.
2. AcrrveuoN oF pLATELETS By THRoMBTN
Thrombin is the most potent physiological platelet activa-
tor (41), a concentration of 0.1 to 1.0 nM will suffice to trigger a half
maximal release reaction. All other activators of human platelets
need concentrations that are one or more orders of magnitude
greater in order to cause the same response.
Among the proteins released by platelets are Factor V, anti-
thrombin III and heparin neutralizing proteins (platelet Factor 4).
The amount of Factor V sequestered in the platelets is roughly
equal to the amount present in the plasma therefore a complete rel-
ease will double the Factors V content of platelet rich plasma (42).
The thrombin that causes the release reaction will also activate the
released Factor V. It has been shown that this activation rather then
the release reaction itself is the rdte limiting factor for the genera-
tion of Factor V activity from triggered platelets (43). The concen-
tration of Factor V in platelet poor plasma is about 25 nM whereas
that of its partner, Factor X is around 200 nM. This may lead one to
think that the contribution of platelet Factor V may be important in
vivo. The aggregation of platelets at sites where the haemostatic
mechanism is active will cause a further increase in the ratio of pla-
telet Factor V to plasma factor V. Still patients with a storage pool
deficiency that are unable to release Factor V from their platelets
do not have an important haemorrhagic diathesis (44). It seems that
only patients lacking Factor V in both platelets andplasma do show
a haemorrhagic syndrome (45). This may be explained by the gene-
rally recognized fact that the normal level of any clotting factor
represents a large functional exaess. As a rule the level of any clot-
ting factor must drop significantly below 10 % before a decrease of
the clotting function becomes apparent.
A second procoagulant function of platelets induced by
thrombin together with collagen is the platelet < flip-flop >> reaction
discovered by Bevers et al. (46). This reaction consists of a transbi-
layer movement of the procoagulant, negatively charged phospho-
lipids (primarily phosphatidyl serine) that as a rule in the resting
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cell are to be found almost exclusively at the inside face of the
membrane. In the presence of collagen and thrombin platelets pro-
duce these procoagulant phospholipids at the outside of the cell
without the cell being disrupted. The precise molecular mechan-
ism of this reaction is not yet clear. Anyhow, platelets thus activat-
ed, offer large amounts of binding sites for the Factors IXu, VIII.,
Xu and Vu at their outer surface so that prothrombinase and the
Factor X activating enzyme can readily form at their surface there.
One patient has been described in which this mechanism is defec-
tive, she suffers from a mild haemorrhagic diathesis (47).
It has been reported that collagen activated platelets can start
coagulation via a Factor XI dependent mechanism and that ADP
activation of platelets triggers coagulation via Factor XII (48).
These findings remain to be confirmed. The recent observation
that platelets release a potent inhibitor of Factor XIu, so that Fac-
tor IX activation by FXI" hardly proceeds in the presence of activat-
ed platelets (49) makes one doubt the importance of contact activa-
tion for in vivo thrombin generation.
3. TnB Josso loop
In the classical view contact factors and haemophilic factors
form the intrinsic pathway and the importance of the role of the
contact factors is derived from the recognized importance of the
anti-haemophilic factors. The activating action of Factor VII on
Factor IX invalidates this argument. The first indications that the
action of the antihaemophilic factors (FVIII and FIX) is not con-
fined to the coagulation pathway started by the contact factors were
obtained by Biggs and Nossell (50), Josso (51) was the first to pos-
tulate that Factor VII can activate Factor IX so that the antihae-
mophilic factors play a role in thromboplastin triggered coagula-
tion. This means that Factor X can be activated either directly by
Factor VII and tissue thromboplastin or indirectly by Factor IXu
(together with Factor VIIIJ that, in its turn has been activated by
Factor VII. It is easy to see that the function of this pathway will
anyhow be dependent upon the amount of thromboplastin avail-
able. The contribution of the direct, one-step action of Factor VII"
on Factor X^ formation will be constant in time and roughly pro-
portional to the concentration of thromboplastin. The contribution
via the pathway VII r IX * X will be small in the beginning of the
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reaction but will increase proportionally with time as the Factor X
activating enzyme - i.e. Factor IXu-builds up. Therefore the rein-
forcement loop constituted by the antihaemophilic factors - which
we propose to call the Josso loop after its discoverer - will gain in
importance when clotting is started by smaller amounts of throm-
boplastin.
The early observations on the interconnections between the
extrinsic and the intrinsic pathway did not get the attention they
deserved until @sterud and Rappaport drew attention to the fact
that the Factor VII thromboplastin complex is capable of activating
Factor IX in a partially purified system (52).Later Zur andNemer-
son (53) Jesty and Silverberg (54) and Marlar and Griffin (55) estab-
lished this pathway without any reasonable doubt.
The physiological importance of the Josso loop is difficult to
ascertain because of the thromboplastin dependent and hence time
dependent effect discussed above. It is tempting to use the Josso-
loop mechanism as a tentative explanation for the clinical observa-
tion that haemophiliacs tend to bleed in thromboplastin poor
organs such as joints, but this can hardly be accepted as a proof of
its importance. Jesty and Silverberg (54) calculate that the activa-
tion of Factor X by Factor VII. is 6 to 7 times faster than the activa-
tion of Factor lX. Zur and Nemerson (53) find a ratio of 10 of the
theoretical maximal velocities but argue that the actual ratio will be
completely dependent upon the thromboplastin concentration.
Van de Besselaar et al. (56) conclude from observations in deficient
human plasma's that the Josso loop may be of no importance in
human plasma. Clearly the issue is not settled as yet.
Kalousek et al. (57) have reported that Factor X is able to acti-
vate Factor IX. This would constitnte a mutual activation interac-
tion that could enhance Factor X activation even without activation
of Factor IX by Factor VII. Their experiments have been carried
out in purified systems that did not contain protein cofactors (F . V
and F'VIID. Any indication as to the physiological significance of
this interaction is lacking at this moment.
4. AcrryarroN oF Facron VII
The current view on the starting mechanism of coagulation is
based on the observation that the proenzyme Factor VII has a non-
neglectable enzymatic activity (58, 59). Once it adsorbes onto tissue
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thromboplastin, the activity of Factor VII is enhanced so as to
become sufficiently important to start the clotting process. It has
been observed however that there exists a more active form of Fac-
tor VII, the two chain Factor VII.. This form can be generated from
the one chain form in a number of different ways. Altman and
Hemker (60) showed, as early as 1968, that the contact activation
mechanism can enhance Factor VII activity in vitro. The cold acti-
vation of Factor VII, involving kallikrein and different other pro-
teins has been well established. It has also been described that Fac-
tor VII can be activated by Factor IXu and by Factor Xu (61, 62). A
very interesting suggestion is made by Silverberg and Jesty (63),
when they claim that a complex of Factor VII, tissue thromboplas-
tin and Factor Xu in the proteolytically active species.
If anywhere, then it is at the level of the activation of Fac-
tor VII that every conceivable reciprocal interaction of clotting
factors has been described whereas any indication of their physio-
logical importance is lacking. It is evident that all biochemical
observations do not necessarily represent reactions that play a role
in (patho)physiology. This being said, it must also be mentioned
that often conclusions are drawn too quickly from clinical observa-
tions. Tradition has it that the scarce observations of a Factor VII
deficiency or of any other rare clotting factor deficiency provoke
speculations as to the physiological importance of a deficiency of
that specific factor. Now some observe a low Factor VII level
(< 5 %) without clinical symptoms whereas others find these
patients severly handicapped. The same holds for Factor XI defi-
ciencies and others. In trying to interprete these data one should be
aware of the following :
a) any really important bleeding syndrome will lead to death
either before or shortly after birth. Only the relatively mild syn-
dromes survive. We remind of the analogy in thrombophilia : AT
III and protein C deficiencies are only known in the heterozygeous
states probably because complete deficiencies are lethal for the
foetus:
b) any deficiency that does not lead to a clinically important
syndrome will more often then not go unnoticed. It must be kept in
mind that the physiological levels of clotting factors as a rule
represent a large excess ofthat factor so that a decrease to as low as
<rc% of the normal level will not cause any overt disease. The
number of deficiencies that are recognized not to cause problems
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will therefore depend on chance findings and hence be under-esti-
mated. This is illustrated by the fact that these disorders tend to
cluster around laboratories that specialize in research on blood coa-
gulation that are backed up by competent clinicians. We thus see
that neither the really important deficiencies nor those without any
clinical consequences will be recognized in routine medical prac-
tice. Therefore it is very hard - if not impossible - to draw conclu-
sions on the mechanism of the blood coagulation process from the
correlation between observed clinical symptoms and the accom-
panying clotting factor deficiencies.
C. INHIBITORY REACTIONS
One may think of several crosslinks between the reactions that
inhibit the clotting process and those that enhance thrombin for-
mation.
The thrombin feedback reactions play an important role here.
As we have discussed before, thrombin will enhance its own for-
mation by activating the factors V and VIII as well as platelets. Any
inhibition of thrombin formation and any reaction that inactivates
thrombin therefore will interfere with this positive feedback. At the
moment it is completely unknown in howfar antithrombin III inhi-
bits thrombin formation because it prevents the activation of Fac-
tor V or Factor VIII etc. Because heparin acts via antithrombin III,
this means that the pathways of heparin action in plasma are to a
large extend unknown at this moment. Also diminution of the
available amount of thrombin will cause a decreased rate of activa-
tion of protein C and therefore prolong the mean lifetime of the
prothrombin - and Factor X activating complexes. Again no quan-
titative data are available that allow an estimate of the importance of
this conceivable pathway.
In the second place one has to reckon wlth competitionfor clot-
ting proteases between procoagulant complexes and protease sca-
vengers. Here more data are availalbe. It has been observed for ins-
tance (64,65) that antithrombin III will attack Factor Xu less readily
in the presence of phospholipids then in free solution and even less
if both phospholipids and Factor V1n1 aro present. To what extend
this phenomenon, observed in (semi)purified systems is operative
in viyo is anybodies guess. The fact that low molecular weight hepa-
rins are efficient antithrombotics and have an enhanced anti Fac-
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tor Xu activity suggests that anti-Factor X" scavenging by AT III-
heparin complexes might be of (patho)physiological importance. It
has also been shown however that there is no direct relation be-
tween anti-Factor X action and antithrombotic properties (66,67).
What holds tor Factor Ku and antithrombin \ in princrple
ff fi T-t7<.ri6e-fo-rraeco:rr<6:&<-
hotds for all surface bound,proteases and all antiproteases. We do
la\nrvsr\ssre.i ._$so_,Fe+#
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c) Because in the specialized laboratory all the clotting factors
are now available in a purified form it is possible to bypass and
shortcut pathways by directly adding the purified activated interme-
diates. Also kinetic studies in whole plasma are now possible
because the concentration of one specific factor can be modified
between zero and very high concentrations by adsorption of that
factor to a specific antibody or by adding the purified factor to the
plasma.
d) Clotting factors that have properties different from the nor-
mal ones occur in rare congenital disorders or can be produced by
chemical modification. If for example the prothrombin, in normal
plasma is replaced by aminidated prothrombin, thrombin will still
be readily formed by prothrombinase, but this aminidated throm-
bin will be unable to activate Factors V and VIII. In such a plasma
the importance of feedback activation of these factors may be stu-
died.
Ifthus appears that there are several possible ways to integrate
the data from modern biochemical studies with the studv of the
clottjng of plasma ex vivo.
Sunauenv
We give a review of modern concepts of the mechanism of blood coa-
gulation. Two main principles goyern this process :
a) activation of proenzymes by limited proteolysis
b) heterogeneous biocatalysis.
The former can be considered common knowledge, the second indi-
cates the fact that three clotting enzymes (Factor VII., IXu and X) cannot
act efficiently unless they are adsorbed on a suitable phospholipid subs-
trate next to a protein cofactor (Tissue Factor (TF), Factors V" and VIII").
On good grounds the importance of the contact activation system for phy-
siological blood coagulation can be doubted. The antihemophilic factors
form a reinforcement loop for the activation of Factor X (Josso loop).
The basis scheme of blood coagulation therefore is :
_.rlx. Yrll^
//' I
VII.TF + X.Va -II
(The arrows indicate activation, the underlining indicate the phospholipid
surface).
This scheme is only the backbone of the reaction sequence, many
other reactions have been described. Thrombin e.g. activates the protein
cofactors V and VIII. Thrombin also activates blood platelets and induces
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them to shed Factor V and to generate patches or procoagulant phospho-
lipids at their surfaces. Also limiting processes are important, e.g. : the
thrombin formed is captured by antiproteases present in the plasma and
Factors Vu and VIII. are inactivated by activated protein C.
Protein C is a vitamin K-dependent plasma protein that can be acti-
vated by thrombin adsorbed to a surface protein of endothelial cells(thrombomodulin).
Apart from the main lines sketched here, many other interactions be-
tween clotting factors have been described. At the moment it is unknown
wether they have physiological significance or are only possible under
non-physiological test conditions.
It even is an open question at the moment what reactions govern the
velocity of thrombin formation in whole plasma.
REsurr,tn
Nous pr6sontons ici un survol des r6actions biochimiques qui amd-
nent d la formation de la thrombine. Deux principes essentiels peuvent
6tre retenus :
a) l'activation de proenzymes par prot6olyse limit6e et
b) la biocatalyse h6t6rogdne.
Le premier principe est un m6canisme universellement admis en bio-
chimie. Le deuxidme indique que trois enzymes de la coagulation (Fac-
teurs VII., IX" et X) ne peuvent atteindre leur efficacit6 maximale que
lorsqu'ils sont adsorb6s sur une surface de phospholipides et en pr6sence
d'un cofacteur (TF. : facteur tissulaire, facteur Vu et facteur VIII"). Si le
' r61e de I'activation par le contact semble al6atoire,la < boucle Josso > for-
m6e pour I'activation du Facteur X, par les facteurs antih6mophiliques(Facteur VIII et IX) apparait importante. Le sch6ma global de la thrombi
no-formation peut donc 6tre repr6sent6 comme suit :
IX.VIII^
--T-
VILT.F. -x.v, -+II
(Les fldches indiquent l'activation, les traits sous les symboles indiquent
la surface phospholipidique).
A c6t6 de ces r6adtioxs principales de nombreuses r6actions annexes
ont 6t6 d6crites. Ainsi la thrombine rend actifs les cofacteurs v et vIII. De
mome la thrombine induit une r6action plaquettaire qui conduit'a la lib6-
ration du facteur V contenus dans leurs granules, produisant ainsi des
phospholipides procoagulants d leur surface.
La thrombine en milieu plasmatique est inactiv6e par des prot6ines
inhibitrices, comme l'antithrombine III et l'u2 macroglobuline.
La thrombine adsorb6e d une prot6ine de la surface de I'endoth6lium(la thrombomoduline) est capable d'activer une autre prot6ine plasmati-
que : la prot6ine c. Une fois activ6e, cette prot6ine d6truit les cofacteurs
Vu et VIII. freinant ainsi la thrombinoformation.
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IX. VIII.
-T
VI I .TF -X .V. - I I
Lem6can ismede la th romb ino fo rma t i ones tdoncconnudansces
pr inc ipes.Cependantunequest ionpr inc ipalerested6trer6solue:quel les
Sontlesinteractionsquid6terminentlavitessedelathrombinoformation
dans le plasma ?
SeusNvetuNc
Er wordt een overzicht gegeven van het biochemisch mechanisme
van de bloedstolling. Twee principes beheersen dit proces :
a) activering van proenzymen door beperkte proteolyse en
b) heterogene biokatalYse
iet eirste wordt bekend verondersteld. Het tweede geeft aan dat stol-
lingsenzymen (de factoren VIIa, IX", X) slechts efficidnt kunnen werken
;i;;ij-g;;rorteerd ziin aan Jen pAospholipide oppervlak tesamen met
.r"llJt enzymatisch hulpeiwit (TF (: weefselfactor), factor vu en fac-
tor VIII").
n iijn gronden om aan het belang van de z'g' contactactivering te
twijreren,ma-ardeantihemofil iefactoren(IXenVIII)vormeneenverster-
kingslus voor de activering van factor X'^ 
-H;i 
grondschema varr de bloedstolling wordt zodoende :
(De pijlen duiden op activaties, de strepen onder de symbolen stellen het
phospholipide oPPervlak voor).'--- 
NuuriOit basisschem a ziin er talrijke andere reacties beschreven' Zo
brengt het thrombine in bloedplaatjes een reactie teweeg die zorgt voor
hetv-erschijnenvanstoll ingsactievephospholipideoppervlakkenengeac-
tiveerde factor V.
Als het thrombine eenmaal gevormd is wordt het weggevangen door
de antiproteasen van het bloedplasma, terwijl het thrombinevormend
."rV- *"tOt geremd doordat een ander bloedeiwit (protein C) wanneer
het'eenmaal geactiveerd is (nl. door thrombine gecomplexeerd met
thrombomod,riine, e"n eiwit dat aan de oppervlakten van endotheel cel-
ten voorkomt) de hulpfactoren Vu en VIII" vernietigt'
ofschoon in grotl lijnen kwilitatief bekend is welke reacties de
hoofdlijnen van het stollingsproces Yormen en welke andere reacties bio-
.fr.-lt:.it mogelijk zijn ulijff het een open vraag welke processen in vivo
snelheidsbepalend zijn.
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BESPREKING
MERLEVEDE. - Hetgeen mij opvalt is dat in uw schema de
factoren II, VII,IX en f ttit'uut staan Dit zijn ook de factoren die
onder invloed van vitamine K van precursoren omgezet 
worden in
stollingsfactoren. Wat is er eerst gekomen in de conceptuele 
voor-
stelling van dit schema: de belangrijke rol van vitamine K of de
experiment.f. nurititfflng Oat deze factoren centraal 
staan ?
HEMKER. - De vitamine K-gevoelige stollingsfactoren 
zijn
ook de zymogene;an de proteolytische enzymen 
van de bloed-
stolling, als men tenminste het contact activeringssysteem' 
op basis
van de argumenten die ik in mijn voordracht noemde' buiten 
be-
schouwing laat.
De experimenten van de laatste paar jaar laten duide.lijk zien
dat dezeproteotytische enzymen de ruggegraat 11 
het bloedstol-
lingsrrrechanisme vormen' Op deze'manier begrijpen wij waarom
vitamine K zo'n ueiangrijte rol speelt' Wij zijn onze stu-dies begon-
nen om t.t *"r*--ni" o" orute antistollingsbehandeling. 
en dus
vandewelk ingvanv i tamineK,beter tebegr i jpenendat isu i tge-
mond in onze 
"o"."pi"tit 
voor;tefling van de rol van de proteoly-
tisch enzYmen.
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VERSTRAETE. - orale anticoagulantia remmen de synthese
van vitamine K afhankelijke stollingseiwitten. De therapeutische
dosering van orale anticoagulantia is dusdanig dat de streefwaarden
van de betrokken stollingseiwitten tussen 10 tot 15 % vanhun uit-gangsconcentratie in het bloed bedragen.
In uw kinetische studies, uiteraard in vitro en met gezuiverde
stollingsfactoren, hebt u aangetoond dat slechts bij vele iug.., .on-
centraties de kinetica van de bloedstolling geremd is. Als men de
rol van thrombine op bloedplaatjes buiten beschouwin graat,wordt
het dan niet moeilijk de antistollingstherapie rationeet te
verklaren ?
HEMKER. - Inderdaad is het zo dat ook bij adequate orale
antistolling de plasma concentraties van de stollingsfactCI*en nog
beduidend hoger ziin dan de concentraties die, in een geisoleerde
stap, een half maximale redactiesnelheid geven.
omdat het geihtegreerde proces van de bloedstolling een sterk
niet{ineair en tegengekoppeld systeem is, mag men daaruit echter
niet concluderen dat het hele systeem ook wel weinig geremd zal
zijn. rn feite is het reconstrueren van de kinetica van tret gehele
systeem op basis van wat wij van de kinetica van de ondeidelen
weten de opgave die ik me voor de komende tien jaar gesteld heb.
Daarom kan ik op uw vraag nog geen exact antwoord geven. Het
lijkt echter wel zeker dat de tegenkoppeling via thrombine naar de
thrombocyt die u noemde, hierbij een belangrijke rol speelt.
i
